WallStSmart

Empro Group Inc. Ordinary shares (EMPG)vsHenry Schein Inc (HSIC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Henry Schein Inc generates 243924% more annual revenue ($13.38B vs $5.48M). EMPG leads profitability with a 13.7% profit margin vs 3.0%. HSIC trades at a lower P/E of 24.6x. HSIC earns a higher WallStSmart Score of 52/100 (C-).

EMPG

Hold

47

out of 100

Grade: D+

Growth: 5.3Profit: 9.0Value: 4.0Quality: 7.5
Piotroski: 6/9Altman Z: 3.11

HSIC

Buy

52

out of 100

Grade: C-

Growth: 4.7Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: 2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EMPG.

HSICUndervalued (+46.8%)

Margin of Safety

+46.8%

Fair Value

$153.40

Current Price

$77.45

$75.95 discount

UndervaluedFair: $153.40Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EMPG4 strengths · Avg: 10.0/10
Return on EquityProfitability
49.2%10/10

Every $100 of equity generates 49 in profit

Operating MarginProfitability
36.1%10/10

Strong operational efficiency at 36.1%

Revenue GrowthGrowth
141.6%10/10

Revenue surging 141.6% year-over-year

Altman Z-ScoreHealth
3.1110/10

Safe zone — low bankruptcy risk

HSIC1 strengths · Avg: 8.0/10
Price/BookValuation
2.7x8/10

Reasonable price relative to book value

Areas to Watch

EMPG4 concerns · Avg: 3.3/10
Price/BookValuation
17.0x4/10

Trading at 17.0x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$143.05M3/10

Smaller company, higher risk/reward

P/E RatioValuation
192.9x2/10

Premium valuation, high expectations priced in

HSIC4 concerns · Avg: 3.5/10
PEG RatioValuation
1.794/10

Expensive relative to growth rate

EPS GrowthGrowth
4.5%4/10

4.5% earnings growth

Profit MarginProfitability
3.0%3/10

3.0% margin — thin

Debt/EquityHealth
1.153/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : EMPG

The strongest argument for EMPG centers on Return on Equity, Operating Margin, Revenue Growth. Revenue growth of 141.6% demonstrates continued momentum.

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book.

Bear Case : EMPG

The primary concerns for EMPG are Price/Book, EPS Growth, Market Cap. A P/E of 192.9x leaves little room for execution misses.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, EPS Growth, Profit Margin. Thin 3.0% margins leave little buffer for downturns.

Key Dynamics to Monitor

EMPG profiles as a growth stock while HSIC is a value play — different risk/reward profiles.

EMPG is growing revenue faster at 141.6% — sustainability is the question.

EMPG generates stronger free cash flow (-16,470), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HSIC scores higher overall (52/100 vs 47/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Empro Group Inc. Ordinary shares

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Empro Group Inc., through its subsidiary, sells healthcare and beauty products in Malaysia and internationally. The company is headquartered in Shah Alam, Malaysia.

Visit Website →

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?